128 related articles for article (PubMed ID: 21951998)
1. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
[No Abstract] [Full Text] [Related]
2. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
3. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
7. Differential apoptosis-inducing effect of quercetin and its glycosides in human promyeloleukemic HL-60 cells by alternative activation of the caspase 3 cascade.
Shen SC; Chen YC; Hsu FL; Lee WR
J Cell Biochem; 2003 Aug; 89(5):1044-55. PubMed ID: 12874837
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferation effects of ponicidin on human myeloid leukemia cells in vitro.
Liu JJ; Huang RW; Lin DJ; Wu XY; Lin Q; Peng J; Pan X; Song YQ; Zhang MH; Hou M; Chen F
Oncol Rep; 2005 Apr; 13(4):653-7. PubMed ID: 15756438
[TBL] [Abstract][Full Text] [Related]
9. Iron-induced cardiac damage: role of apoptosis and deferasirox intervention.
Wang Y; Wu M; Al-Rousan R; Liu H; Fannin J; Paturi S; Arvapalli RK; Katta A; Kakarla SK; Rice KM; Triest WE; Blough ER
J Pharmacol Exp Ther; 2011 Jan; 336(1):56-63. PubMed ID: 20947636
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox--an oral agent for chronic iron overload.
Vanorden HE; Hagemann TM
Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox (Exjade): a new iron chelator.
Med Lett Drugs Ther; 2006 Apr; 48(1233):35-6. PubMed ID: 16625144
[No Abstract] [Full Text] [Related]
12. Deferasirox: the new oral iron chelator.
Dubey AP; Sudha S; Parakh A
Indian Pediatr; 2007 Aug; 44(8):603-7. PubMed ID: 17827637
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox in thalassemia patients with end-stage renal disease.
Beydoun HG; Saliba AN; Taher AT
Am J Hematol; 2016 Oct; 91(10):E456-7. PubMed ID: 27342388
[No Abstract] [Full Text] [Related]
14. Exjade (ICL 670): A new oral iron chelator.
Agarwal MB
J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
[TBL] [Abstract][Full Text] [Related]
15. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
[TBL] [Abstract][Full Text] [Related]
16. A novel polysaccharide, isolated from Angelica sinensis (Oliv.) Diels induces the apoptosis of cervical cancer HeLa cells through an intrinsic apoptotic pathway.
Cao W; Li XQ; Wang X; Fan HT; Zhang XN; Hou Y; Liu SB; Mei QB
Phytomedicine; 2010 Jul; 17(8-9):598-605. PubMed ID: 20092988
[TBL] [Abstract][Full Text] [Related]
17. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Ferrajoli A; Faderl S; Van Q; Koch P; Harris D; Liu Z; Hazan-Halevy I; Wang Y; Kantarjian HM; Priebe W; Estrov Z
Cancer Res; 2007 Dec; 67(23):11291-9. PubMed ID: 18056455
[TBL] [Abstract][Full Text] [Related]
18. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis of human leukemia HL-60 cells and murine leukemia WEHI-3 cells induced by berberine through the activation of caspase-3.
Lin CC; Kao ST; Chen GW; Ho HC; Chung JG
Anticancer Res; 2006; 26(1A):227-42. PubMed ID: 16475703
[TBL] [Abstract][Full Text] [Related]
20. Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa.
Pal HC; Sehar I; Bhushan S; Gupta BD; Saxena AK
Toxicol In Vitro; 2010 Sep; 24(6):1599-609. PubMed ID: 20600805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
